J&J Hedges On 2025 Pharma Revenue Outlook
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.
You may also be interested in...
Johnson & Johnson laid out long-term revenue growth guidance and plans for its Innovative Medicines pipeline during an R&D day.
After reaching patent settlements with biosimilar drug makers, the company expects to retain exclusivity of its top-selling drug longer than initially expected.
Novartis and Johnson & Johnson will be the first two big pharmas to release second quarter financial results, and both have faced recent patent case developments for top-selling drugs.